A MEA is a MEA is a MEA? Sequential decision making and the impact of different managed entry agreements at the manufacturer and payer level, using a case study for an oncology drug in England

被引：0

作者：

Nasuh C. Buyukkaramikli

Peter Wigfield

Men Thi Hoang

机构：

[1] Janssen Pharmaceutica NV,Institute for Global Health Innovations

[2] Ingress Health Nederland BV,Faculty of Medicine

[3] Duy Tan University,undefined

[4] Duy Tan University,undefined

来源：

The European Journal of Health Economics | 2021年 / 22卷

关键词：

Managed entry agreements; Risk sharing contracts; Cost-effectiveness; Health economics; Sequential decision making; Payer and manufacturer views; Reimbursement; C7; D61; I110; I180;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

页码：51 / 73

页数：22

共 2 条

[1] A MEA is a MEA is a MEA? Sequential decision making and the impact of different managed entry agreements at the manufacturer and payer level, using a case study for an oncology drug in England
Buyukkaramikli, Nasuh C.
Wigfield, Peter
Hoang, Men Thi
EUROPEAN JOURNAL OF HEALTH ECONOMICS, 2021, 22 (01): : 51 - 73
[2] A MEA IS A MEA IS A MEA? ANALYSIS OF THE SEQUENTIAL DECISION MAKING AND THE IMPACT OF DIFFERENT OPTIMIZED MANAGED ENTRY AGREEMENTS AT THE MANUFACTURER &PAYER LEVEL, USING A CASE STUDY OF AN ONCOLOGY DRUG IN THE UK
Buyukkaramikli, N. C.
Wigfield, P.
Hoang, T. M.
VALUE IN HEALTH, 2019, 22 : S446 - S446

← 1 →